TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14670571

Group type: EXPERIMENTAL
Intervention: Complete callosotomy patients
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Withdrawal of visual control in split-brain patients
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 17
Study: 11406789

Group type: EXPERIMENTAL
Intervention: TiO2-blasted implants
Number of subjects: 50

Group type: COMPARATOR
Intervention: Machined implants
Number of subjects: 50
Study: 8988821

Group type: EXPERIMENTAL
Intervention: Epidural ketamine + morphine with lidocaine before surgical incision
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia (group EA)
Number of subjects: 45

Group type: COMPARATOR
Intervention: General anaesthesia (group G)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Epidural ketamine + morphine with lidocaine after skin incision (group EA)
Number of subjects: 45
Study: 8102511

Group type: EXPERIMENTAL
Intervention: Vitamin E (1600 IU/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 29793563

Group type: EXPERIMENTAL
Intervention: Acupressure (Group 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham (Group 2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (Group 3)
Number of subjects: 0
Study: 27824758

Group type: EXPERIMENTAL
Intervention: misoprostol‐cervical Foley
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Foley‐oxytocin
Number of subjects: 491

Group type: COMPARATOR
Intervention: misoprostol alone
Number of subjects: 491

Group type: COMPARATOR
Intervention: Foley alone
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: misoprostol‐Foley
Number of subjects: 491
Study: 24034302

Group type: EXPERIMENTAL
Intervention: CRT responders (n=28)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Combination of QRS duration and mean energy in the high frequency band
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Maximum energy in the high frequency band
Number of subjects: 38
Study: 22542366

Group type: EXPERIMENTAL
Intervention: Etonogestrel (ENG)‐releasing implant inserted 24‐48 h after delivery (implant group; n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nothing (control group; n=20)
Number of subjects: 40
Study: 20175754

Group type: EXPERIMENTAL
Intervention: TAP block
Number of subjects: 364
Study: 18650111

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus supportive care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supportive care alone
Number of subjects: 0
Study: 16739369

Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg
Number of subjects: 996
Study: 12954840

Group type: EXPERIMENTAL
Intervention: Erythropoietin and preoperative autologous donation (Group 1)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Erythropoietin alone (Group 2)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Preoperative autologous donation alone (Group 3)
Number of subjects: 240
Study: 10932029

Group type: EXPERIMENTAL
Intervention: Amlodipine (Norvasc)
Number of subjects: 0
Study: 9014795

Group type: EXPERIMENTAL
Intervention: 100% oxygen at rest
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 100% oxygen during cycle ergometry
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Continuous inspired oxygen during treadmill exercise testing
Number of subjects: 21

Group type: COMPARATOR
Intervention: Air during treadmill exercise testing
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Transient inhalations of pure nitrogen
Number of subjects: 21
Study: 1354392

Group type: EXPERIMENTAL
Intervention: Intravenous 50 mg bolus of chimaeric anti-CD4 monoclonal antibody (cM-T412)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 50 mg weekly for four consecutive weeks of chimaeric anti-CD4 monoclonal antibody (cM-T412)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 6147836

Group type: EXPERIMENTAL
Intervention: LORMetazepam 2 mg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: FLUNitrazepam 2 mg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: FLURazepam 30 mg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: DIAZepam 10 mg
Number of subjects: 35
Study: 30949243

Group type: EXPERIMENTAL
Intervention: Heel lift group receiving pre-fabricated 12 mm in-shoe heel lifts (Clearly Adjustable®)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Calf muscle eccentric exercise program (twice a day, 7 days a week, for 12 weeks)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Heel lift group
Number of subjects: 92

Group type: COMPARATOR
Intervention: Calf muscle eccentric exercise group
Number of subjects: 92
Study: 28528475

Group type: EXPERIMENTAL
Intervention: 200 μg/day selenium supplements
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 26865420

Group type: EXPERIMENTAL
Intervention: Breathe Right Nasal Strip (BRNS)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Breathe Right Nasal Strip (BRNS) + Decongestant
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo Strip
Number of subjects: 26
Study: 25379858

Group type: COMPARATOR
Intervention: TAC-PLAC (tacrolimus placebo)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: TAC-STER (tacrolimus short-term steroid)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 156
Study: 22115985

Group type: EXPERIMENTAL
Intervention: ICD providing continuous intracardiac ST monitoring (ST group)
Number of subjects: 103

Group type: COMPARATOR
Intervention: ICD without continuous intracardiac ST monitoring (Control group)
Number of subjects: 103
Study: 19858777

Group type: EXPERIMENTAL
Intervention: Budesonide 400 microg twice daily for 1 month, then 200 microg twice daily for 5 months
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Budesonide 100 microg twice daily for 1 year
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Budesonide used periodically for exacerbations
Number of subjects: 113

Group type: COMPARATOR
Intervention: Disodium cromoglycate (DSCG) for 18 months
Number of subjects: 113
Study: 18022468

Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg intramuscularly (Group T)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 75 mg intramuscularly (Group D)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (saline) (Group P)
Number of subjects: 36
Study: 15617966

Group type: EXPERIMENTAL
Intervention: Implants placed in grafted bone (222 implants)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Brånemark implants in non-grafted bone (75 implants)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Implants placed in grafted bone
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Implants with low primary stability (20 implants)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Failed implants
Number of subjects: 39
Study: 12102059

Group type: EXPERIMENTAL
Intervention: Extremely violent comic book
Number of subjects: 117

Group type: COMPARATOR
Intervention: Mildly violent comic book
Number of subjects: 117
Study: 10213444

Group type: EXPERIMENTAL
Intervention: High contrast acuity
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Spatial vision measures under conditions of reduced contrast or luminance, or glare
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Stereopsis
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Color discrimination
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Peripheral fields under conditions of divided attention
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Aging function with a time constant of approximately 15 years
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Standard visual acuity
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: All spatial vision functions
Number of subjects: 900
Study: 7607378

Group type: EXPERIMENTAL
Intervention: 20 mg oxybutynin administered intravesically
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (40 ml sterile sodium chloride solution) administered intravesically
Number of subjects: 39
Study: 1977153

Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Cetirizine (evening administration)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Cetirizine (morning administration)
Number of subjects: 61
Study: 707970

Group type: EXPERIMENTAL
Intervention: L-tryptophan (0.5-1.0 g t.i.d.)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Doxepin (25-50 mg t.i.d.)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Chlorimipramine (25-50 mg t.i.d.)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Pre-drug scores (29 patients)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Matched reference group (20 healthy volunteers)
Number of subjects: 29
Study: 31227286

Group type: EXPERIMENTAL
Intervention: 1,000 IU hCG at the time of GnRHa trigger and placebo at the time of vaginal oocyte retrieval (VOR)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Placebo at the time of GnRHa trigger and 1,500 IU hCG at the time of VOR
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Adjuvant hCG given at VOR
Number of subjects: 30

Group type: COMPARATOR
Intervention: Adjuvant hCG given at the time of trigger
Number of subjects: 30
Study: 29238824

Group type: EXPERIMENTAL
Intervention: Gabapentin (1200 mg preoperatively and 600 mg 3 times a day postoperatively)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Active placebo (lorazepam, 0.5 mg preoperatively followed by inactive placebo postoperatively)
Number of subjects: 410
Study: 27472216

Group type: EXPERIMENTAL
Intervention: IOL implantation
Number of subjects: 114

Group type: COMPARATOR
Intervention: Contact lens correction
Number of subjects: 114
Study: 24946631

Group type: EXPERIMENTAL
Intervention: Acupuncture, applied to corresponding acupoints based on affected lumbar vertebras, once every day for 30 min, for 3 weeks.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Moxibustion at Dazhui (GV 14) and Guanyuan (CV 4), warm moxibustion applied once every other day for 1 hour, for 3 weeks.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both interventions (acupuncture and moxibustion)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 40
Study: 23043386

Group type: EXPERIMENTAL
Intervention: PEG‐IFN/ribavirin (P/R) for 12 weeks
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: PEG‐IFN for 72 weeks
Number of subjects: 329

Group type: COMPARATOR
Intervention: Observational control for 72 weeks
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: PEG‐IFN/ribavirin (P/R) for a total of 72 weeks with 24 weeks follow‐up off‐therapy
Number of subjects: 329
Study: 20377844

Group type: EXPERIMENTAL
Intervention: Decision aid
Number of subjects: 596

Group type: COMPARATOR
Intervention: Pamphlet
Number of subjects: 596
Study: 18055932

Group type: EXPERIMENTAL
Intervention: Integrated treatment
Number of subjects: 547

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 547
Study: 16784879

Group type: EXPERIMENTAL
Intervention: valdecoxib 10 mg qd
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: rofecoxib 25 mg qd
Number of subjects: 530

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 530
Study: 12074059

Group type: EXPERIMENTAL
Intervention: Focused minimally invasive parathyroidectomy (MIP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Open parathyroidectomy
Number of subjects: 100
Study: 10512278

Group type: EXPERIMENTAL
Intervention: Morphine plus lysine acetyl salicylate (LAS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 50
Study: 8766480

Group type: EXPERIMENTAL
Intervention: Promethazine
Number of subjects: 0
Study: 2030245

Group type: EXPERIMENTAL
Intervention: Parent-training treatment (average of 44.8 hours of professional contact, including 23.3 hours of phone contacts)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Service traditionally provided by the juvenile court and community (estimated more than 50 hours of treatment)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Parent-training treatment
Number of subjects: 55
Study: 7139000

Group type: EXPERIMENTAL
Intervention: Fear-relevant content (snake-slide), 25 trials
Number of subjects: 40

Group type: COMPARATOR
Intervention: Neutral content (rectangular black geometric shape), 25 trials
Number of subjects: 40
Study: 31045775

Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Pregabalin 600 mg
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54

Group type: COMPARATOR
Intervention: Overall opioid consumption
Number of subjects: 54

Group type: COMPARATOR
Intervention: BSHS (Burn Specific Health Scale)
Number of subjects: 54
Study: 28835404

Group type: EXPERIMENTAL
Intervention: Erenumab 70 mg every 4 weeks for up to 5 years
Number of subjects: 383
Study: 25815710

Group type: EXPERIMENTAL
Intervention: Daily walking (30-60 minutes to achieve 10,000 steps/day for 4 weeks)
Number of subjects: 65
Study: 23727518

Group type: EXPERIMENTAL
Intervention: Extraperitoneal cesarean section (ECS)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Transperitoneal cesarean section (TCS)
Number of subjects: 54
Study: 21852252

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) injections
Number of subjects: 306

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 306
Study: 19122539

Group type: EXPERIMENTAL
Intervention: Maintenance treatment with antidepressants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naturalistic studies in anxiety disorders
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term pharmacological treatment
Number of subjects: 0
Study: 17910229

Group type: COMPARATOR
Intervention: Group 1: resin composite restoration without horizontal self‐threading pins or flowable composite (control group)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Group 2: resin composite restoration without horizontal self‐threading pins but with a 2 mm thickness of the flowable composite
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Group 3: resin composite restoration with two horizontal self‐threading pins in the buccal cusp but without flowable composite
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Group 4: resin composite restoration with two horizontal self‐threading pins in the buccal cusp and flowable composite with a thickness of 2 mm
Number of subjects: 64
Study: 15472792

Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus rhamnosus GG (LGG) preparation (1-5 x 10^10 cfu/dose)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus rhamnosus GG (LGG) preparation
Number of subjects: 17
Study: 10385840

Group type: EXPERIMENTAL
Intervention: Stimulant therapy
Number of subjects: 130

Group type: COMPARATOR
Intervention: Normal control population (N = 31)
Number of subjects: 130
Study: 8686677

Group type: EXPERIMENTAL
Intervention: Fränkel function regulator or Harvold activator (treatment)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 42
Study: 1887411

Group type: EXPERIMENTAL
Intervention: Bifidumbacterine
Number of subjects: 43

Group type: COMPARATOR
Intervention: Salazopyridazine
Number of subjects: 43
Study: 6862292

Group type: EXPERIMENTAL
Intervention: Histologic grade and size of residual tumor after surgery
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Histologic type
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Stage of tumor progression
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: State of tumor capsules in Stage I
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Ascites
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Continued chemotherapy
Number of subjects: 494
Study: 31916717

Group type: EXPERIMENTAL
Intervention: Amniotic fluid group (5mL/kg synthetic amniotic fluid)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: EPO group (RhuEPO dissolved in synthetic amniotic fluid)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (routine feeding protocol without any administration)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 150
Study: 29406482

Group type: EXPERIMENTAL
Intervention: CaHA with triamcinolone acetate
Number of subjects: 20

Group type: COMPARATOR
Intervention: CaHA with sham saline
Number of subjects: 20
Study: 24679362

Group type: EXPERIMENTAL
Intervention: WB‐MWM
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: HVLA
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 21938518

Group type: EXPERIMENTAL
Intervention: Pulmonary vein antral isolation (PVAI)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Pulmonary vein antral isolation plus additional limited ablation (PVAI + CS)
Number of subjects: 42
Study: 20156949

Group type: EXPERIMENTAL
Intervention: Milnacipran 200 mg/day
Number of subjects: 884

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 884
Study: 18245215

Group type: EXPERIMENTAL
Intervention: Training with patient-actors
Number of subjects: 140

Group type: COMPARATOR
Intervention: Training with manikins
Number of subjects: 140

Group type: COMPARATOR
Intervention: Teamwork training
Number of subjects: 140
Study: 15846460

Group type: EXPERIMENTAL
Intervention: Montelukast 3.5 mg intravenous dose in children
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Montelukast 7 mg intravenous dose in adults
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Montelukast 5.25 mg intravenous dose in children (suggested from trial simulations)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Montelukast (general)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Montelukast (with TBW as covariate)
Number of subjects: 0
Study: 11916954

Group type: EXPERIMENTAL
Intervention: Acute Insulin Response (AIR)
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Intact Proinsulin (PI)
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Split Proinsulin (PI)
Number of subjects: 903
Study: 10328634

Group type: EXPERIMENTAL
Intervention: Low-dose vitamin-mineral tablets
Number of subjects: 1753

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1753
Study: 8734341

Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg three times daily for 3 days)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Mental stress
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Soup meal
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 29
Study: 1761452

Group type: EXPERIMENTAL
Intervention: Ceftibuten 400 mg once a day
Number of subjects: 58

Group type: COMPARATOR
Intervention: Cefaclor 250 mg every 8 h
Number of subjects: 58
Study: 6360773

Group type: EXPERIMENTAL
Intervention: Cicloxilic acid (240 mg/day for 1 month)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31215111

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 40 mg
Number of subjects: 60
Study: 29169294

Group type: EXPERIMENTAL
Intervention: Weiss Functional Impairment Rating Scale (WFIRS) ratings from patients with ADHD
Number of subjects: 62

Group type: COMPARATOR
Intervention: Simulation condition (individuals instructed to feign ADHD)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Genuine ADHD patients
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Weiss Functional Impairment Rating Scale (WFIRS)
Number of subjects: 62
Study: 27692128

Group type: EXPERIMENTAL
Intervention: BFC group (BUD/FM 160/4.5 μg twice daily)
Number of subjects: 91

Group type: COMPARATOR
Intervention: ICS group (budesonide 400 μg twice daily or equivalent dose of ICS)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 91

Group type: COMPARATOR
Intervention: ICS group
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: BFC group
Number of subjects: 91
Study: 24532526

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 50
Study: 22974412

Group type: EXPERIMENTAL
Intervention: Metformin glycinate (1,050.6 mg once daily for the first month, then force-titrated to twice daily for the second month)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 20349666

Group type: COMPARATOR
Intervention: Sevoflurane (0.5‐1.3% end‐tidal)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Propofol (50‐200 mg/kg/min)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Sevoflurane (in women)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Propofol (in women)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Sevoflurane (in men)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Propofol (in men)
Number of subjects: 198
Study: 17666196

Group type: EXPERIMENTAL
Intervention: Renin-angiotensin-aldosterone system blockade
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thiazide diuretics
Number of subjects: 0
Study: 17356181

Group type: EXPERIMENTAL
Intervention: Cross‐cultural adaptation of study instruments
Number of subjects: 0
Study: 15589485

Group type: EXPERIMENTAL
Intervention: 10 mg of simvastatin
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: 40 mg of simvastatin
Number of subjects: 308

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 308
Study: 10698809

Group type: EXPERIMENTAL
Intervention: Nortriptyline (25 mg/day to 100 mg/day)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Fluoxetine (10 mg/day to 40 mg/day)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 9083608

Group type: EXPERIMENTAL
Intervention: Fenfluramine (1.0, 1.5, or 2.0 mg/kg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.4 mg/kg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1524917

Group type: EXPERIMENTAL
Intervention: Topical metronidazole gel
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 11
Study: 3904134

Group type: EXPERIMENTAL
Intervention: diethylstilbestrol (DES)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: estramustine phosphate (Emcyt)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both DES and Emcyt
Number of subjects: 30